PharmaShots | Incisive News in 3 Shots

Subscribe Now

Obstructive Hypertrophic Cardiomyopathy

BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

May 17, 2021

BMS Presents Clinical and RWE Data of Mavacamten for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

BMS Presents Clinical and RWE Data of Mavacamten for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

May 4, 2021

BMS Reports the US FDA's Acceptance of NDA for Mavacamten to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

BMS Reports the US FDA's Acceptance of NDA for Mavacamten to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

March 22, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us